Making billions (of cells) with adherent cell cultures

Cell & Gene Therapy Insights 2021; 7(11), 1533

10.18609/cgti.2021.205

Published: 6 December 2021
FastFacts
Catherine Siler


Watch the video or read the poster to learn about:

  • Adherent platform options to fit the needs of your process and facility
  • Seed train considerations
  • Understanding of process parameters, cross-platform applicability and platforms that facilitate process characterization/control
  • Implementing automation for process consistency

Catherine Siler is an accomplished Field Application Scientist for Corning Life Sciences, with a PhD in Biology from Johns Hopkins University. Dr Siler enables scientists and researchers in the life science industry to overcome challenges with cell culture and scale-up for clinical manufacturing of advanced therapies, and utilizes her research and teaching experience to drive the adoption of an industry-leading global product portfolio of innovative single-use consumables for research, process development and bioprocessing applications.